secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clene Inc. (CLNN)
CIK:        0001822791
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001437749-24-015212
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clene Q1 net loss $11.1M ($0.09/shr); cash $27.9M; VISIONARY-MS data positive
-----------------------------------------------------------------------------

- Cash, equivalents and marketable securities $27.9M at Mar 31, down from $35.0M at Dec 31, 2023; expected to fund operations into Q4 2024.
- Net loss $11.1M ($0.09/shr) vs $11.8M ($0.15/shr) YoY; R&D expenses fell to $5.9M from $7.4M.
- Long-term VISIONARY-MS extension: significant vision improvement (up to 38 letters, p<0.001) and cognition (SDMT +29 points, p<0.001).
- Received $7.3M NIH sub-award for ALS Expanded Access Program; company advancing FDA discussions for NDA filing in H2 2024.
- Peer-reviewed publication in ACS journal characterized CNM-Au8 protein corona supporting neuroprotective mechanism.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822791/000143774924015212/0001437749-24-015212-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822791/000143774924015212/clnn20240202_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-015212

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer